Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not
meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that in the TASKi3 Phase 2b clinical trial in rheumatoid arthritis (RA) patients who had failed to respond to at least one biologic treatment, the group treat...
Cardiovascular Fitness Not Affected by Cancer Treatment
GUMC Researchers Identify Simple Test To Help Survivors Start Exercise Routine Based on Current Cardiovascular Fitness Level
WASHINGTON, May 28 /PRNewswire-USNewswire/ -- The cardiovascular fitness level of cancer survivors is not
affected by many standard cancer therapies, say researchers fr...
AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors
Early-stage renal masses should be treated with nephron-sparing approaches when possible
LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- Radical nephrectomy (complete removal of the affected kidney) is not
the best treatment for most small kidney tumors because it puts patients at risk fo...
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
WAYNE, N.J. and EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that a Phase 3 trial evaluating Nexavar(R) (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma was s...
American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought
--Practice Changing Study Calls on Doctors to Stop Prescribing Potent Heartburn Medications to Asthma Patients Without Frequent Symptoms of Gastric Reflux--
WASHINGTON, April 8 /PRNewswire-USNewswire/ -- For nearly 20 years, it was believed that severe asthma symptoms such as coughing, wheezi...
Elbow Ligament Reconstruction Appears Not to Affect Future Professional Advancement in Baseball
Athletes Who Have UCL Reconstruction Prior to Being Drafted Perform at Similar Level as Those Without Reconstruction
LAS VEGAS, Feb. 28 /PRNewswire-USNewswire/ -- New research presented at the 2009 American Orthopaedic Society of Sports Medicine Specialty Day in Las Vegas suggests that elbo...
Experience Not Always the Best Prescription for Snowblowers
New study finds experience does not
always keep hands injury-free
LAS VEGAS, Feb. 27 /PRNewswire-USNewswire/ -- Snowblower-related injuries to the hand have been on the rise in recent years, with more than 5,000 injuries reported each year in the United States. Many of those injuries might ...
Octogenarians: Not Too Old for Joint Replacement
New study finds total knee replacement surgery can offer significant benefits to patients in their 80s
LAS VEGAS, Feb. 26 /PRNewswire-USNewswire/ -- Knee replacement ( http://orthoinfo.aaos.org/topic.cfm?topic=A00389 ) surgery can improve the quality of life even for very elderly patients, ...
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP ) announced today results of its initial
Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential
treatment of children with asthma. The Company announced that the clinical
AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
LONDON, Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not
meet its co-primary endpoints: asthma control as assessed by changes from baseline i...
Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
New study questions ability of human-animal hybrids to generate stem cells
WORCESTER, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Advanced Cell Technology, Inc. (OTC Pink Sheets: ACTC) and its collaborators reported today that human oocytes (or 'eggs') have the capacity to extensively reprogram...
Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief
HONOLULU, Jan. 28 /PRNewswire/ -- Researchers at Brigham and Women's
Hospital found that patients taking cannabinoid medicines for pain may be
getting "high," but these effects were unrelated to relief from their pain
symptoms. Results of their study, one of the first to examine the addictive...
Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research
HOLLYWOOD, Fla., Jan. 19 /PRNewswire/ -- Stents can be placed in the brain to treat a stroke as it's occurring, suggests preliminary data being presented at the 21st Annual International Symposium on Endovascular Therapy (ISET).
Stents have long been used to open up blocked blood vessels in t...
Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
EMERYVILLE, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that an independent
Data Safety Monitoring Board (DSMB) has determined that the current clinical
trials of Viprinex(TM) for the treatment of acute ischemic stroke are...
Soft Contact Lenses Do Not Lead to 'Myopic Creep' in Children, Study Shows
Largest randomized trial of its kind shows no clinically meaningful
difference between contacts and glasses for progression of nearsightedness
JACKSONVILLE, Fla., Nov. 12 /PRNewswire/ -- Soft contact lens wear does
not result in clinically significant acceleration in the development of
Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
- Study showed no consistent differences in bone mineral density at the
lumbar spine and total hip between Advair Diskus 250/50 (fluticasone
propionate and salmeterol inhalation powder) and salmeterol
- Study provides support for long term use of Advair(R) in patients
Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
American Association for Cancer Research Aims to Raise Awareness about
the Importance of Clinical Trial Participation
PHILADELPHIA, Sept. 24 /PRNewswire/ --
-- Most Americans with cancer would be receptive to participating in clinical trials if they knew about them. ...
Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal
WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ -- The Department of
Justice announced today that it will not
oppose a proposal by the CEO
Roundtable on Cancer (CRC) to develop and publicize model contract language
for clinical trials of potential new cancer treatments. The Department said
Task Force Says Men Age 75 and Older Should Not Be Screened For Prostate Cancer
/CAUTION -- ADVANCE FOR RELEASE AT 5 P.M. EDT MONDAY, AUG. 4/
/ADVANCE/ ROCKVILLE, Md., Aug. 4 -- Men age 75 and older should not
screened for prostate cancer, and younger men should discuss the benefits
and harms of the prostate-specific antigen (PSA) test with their clinicians
Soyfoods Do Not Impact Sperm Count
WASHINGTON, July 24 /PRNewswire-USNewswire/ -- Headlines claiming "soy
products lower sperm count" do not
tell the whole story. The small scale,
preliminary study that Dr. Jorge Chavarro, published online in Human
Reproduction, is based on recollected intake of soyfoods and not
Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies
SOUTH EASTON, Mass., July 1 /PRNewswire-FirstCall/ -- Pressure
BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today announced that scientists
from the New York University ("NYU") School of Medicine and the Brooklyn
Hospital Center presented results yesterday on advances they made in the
areas of b...
DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
REYKJAVIK, Iceland, June 30 /PRNewswire-FirstCall/ -- deCODE genetics
(Nasdaq: DCGN ) today announced positive topline results from its latest
clinical pharmacology study of DG041, the company's first-in-class
antagonist of the EP3 receptor for prostaglandin E2, developed as a
Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
PHILADELPHIA, May 13 /PRNewswire-USNewswire/ -- In women at increased
risk for breast cancer, adding a screening ultrasound examination to
routine mammography revealed 28 percent more cancers than mammography
alone. However, the additional ultrasound exam substantially increased the
rates of f...
Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
BETHESDA, Md., May 5 /PRNewswire/ -- Vaccines don't just keep children
healthy, they also lead to more productive adult workers who can earn
higher wages and save more money, according to Dr. David E. Bloom, a labor
economist at the Harvard School of Public Health.
Bloom, who has studied the...
Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
NEW YORK, April 8, 2008 /PRNewswire/ -- If you're suffering from back
pain and unable to find relief, it may be because the real cause of your
pain -- weak, stressed and damaged muscles, not
your spine -- has never
been recognized or treated, says Norman Marcus, M.D., one of the nation's
Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
-Webcast to Be Held at 4:30 p.m. ET today-
SAN CARLOS, Calif., March 17 /PRNewswire-FirstCall/ -- Nuvelo, Inc.
(Nasdaq: NUVO ) today announced that data from the Phase 2 program in
catheter occlusion (CO), known as SONOMA-3 (Speedy Opening of
Non-functional and Occluded cathete...
GSK Does Not Option XL784 for Further Development
SOUTH SAN FRANCISCO, Calif., Jan. 18 /PRNewswire-FirstCall/ --
Exelixis, Inc. (Nasdaq: EXEL ) today announced that GlaxoSmithKline (GSK)
has decided not
to exercise its option to license XL784 for further
development and commercialization. Exelixis previously announced that XL784
failed to me...
Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
BEVERLY HILLS, Calif., Jan. 15 /PRNewswire/ -- Zetia (ezetimibe) "may
not actually prevent heart attacks and strokes," according to the
long-awaited results of the Enhance trial. Typically, patients "take Zetia
in the form of Vytorin (ezetimibe and simvastatin), which combines Zetia
Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA
Consumers Union Calls on Hospitals to Invest More Resources and Take
Aggressive Steps to Prevent MRSA Infections
WASHINGTON, Dec. 11 /PRNewswire-USNewswire/ -- U.S. healthcare
facilities aren't doing enough to protect patients from
Methicillin-resistant Staphylococcus aureus (MRSA) infecti...
New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need
WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- The following statement
was released today by Pamela W. Barnes, President and Chief Executive
Officer of the Elizabeth Glaser Pediatric AIDS Foundation:
"Four years after the President's Emergency Plan for AIDS Relief
(PEPFAR) began funding trea...
FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
HENDERSON, Nev., Nov. 20 /PRNewswire/ -- FDA spokesman, Brad Swezey,
affirmed to the Wall Street Journal (WSJ) yesterday that the FDA had not
received any reports of patient injuries or adverse effects related to use
of the eyelash product the agency seized last Friday. According to its Novem...
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
- Response at 12 weeks is a powerful predictor of eventual treatment success -
BOSTON, Nov. 2 /PRNewswire/ -- Roche today announced final results from
the REPEAT study, which demonstrated that treatment with once-weekly
PEGASYS(R) (peginterferon alfa-2a) and dai...
Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
DALLAS, Nov. 1 /PRNewswire-USNewswire/ -- Death resulting from
influenza, often referred to as "the flu," is more common among individuals
with heart disease than among patients with any other chronic medical
condition. However, according to a new nationwide survey of heart disease
Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
NEW ORLEANS and PITTSBURGH, Oct. 22 /PRNewswire-FirstCall/ -- Data
presented at the 2007 Annual Scientific Meeting of NAASO, The Obesity
Society, found that patient satisfaction with alli(R) (orlistat 60mg), the
only FDA- approved, over-the-counter (OTC) weight loss product, was
connected to t...
Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
Survey Shows Nearly Three-Quarters of Women Struggle in Managing Their Daily Lives
ATLANTA, Oct. 10 /PRNewswire/ -- New findings from the Women Living
Positive survey show a communication gap between women living with HIV and
their health care providers when it co...
New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
CONCORD, Mass., Oct. 2 /PRNewswire/ -- Many studies have suggested that
moderate red wine consumption is beneficial to cardiovascular health. But
what if you'd like to skip the alcohol? Take heart: laboratory research,
just presented at the WINEHEALTH 2007 conference in Bordeaux, France,
Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
The once-daily HIV treatment would greatly increase effectiveness for
patients, but Gilead Sciences and Merck and Co. have failed to register it in countries where it is needed most
LOS ANGELES, Sept. 10 /PRNewswire-USNewswire/ -- AIDS Healthcare
Foundation (AHF) today calle...
You May Have a Thyroid Problem and Not Know It - Particularly If You're Over 60, Says a New Harvard Medical School Report
BOSTON, Aug. 9 /PRNewswire-USNewswire/ -- Doctors often mistake the
symptoms of thyroid disease for another disorder such as heart failure,
high cholesterol, or even dementia, says a new edition of a report from
Harvard Medical School. The symptoms of thyroid diseases are so
Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Levodopa Remains the Most Widely Prescribed Drug for Parkinson's Disease, According to a New Report from Decision Resources
WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms focusing on pharmaceutical and